Pcr her2 breast cancer12/30/2023 More than half of patients with metastatic HER2 + disease are diagnosed de novo, further demonstrating that most patients presenting with early disease are cured 6. Currently, survival rates exceed 90% in HER2 + early breast cancer (EBC) treated with chemotherapy and dual antibody therapy 5. The dependence of the tumour on HER2, coupled with effective HER2-targeted drugs such as trastuzumab, pertuzumab and most recently, tucatinib and trastuzumab deruxtecan (T-DXd), have contributed to these survival improvements in patients with HER2-positive (HER2 +) BC 4. However, newer and novel therapeutic strategies have led to markedly improved survival outcomes. Advanced BC was considered incurable, and treatment was purely palliative. Until this point, triple-negative and HER2-overexpressing disease were widely regarded as the most aggressive BC histologies, with unfavourable prognoses. The discovery that amplification or overexpression of HER2 was associated with extremely poor survival in BC ultimately led to the development of a monoclonal antibody (mAb) to HER2, trastuzumab 3 (Box 1). The field was energized in 1978 when the first tyrosine kinase, epidermal growth factor receptor (EGFR), was discovered followed by the identification of the neu or HER2 (also known as ERBB2) gene in 1984 1, 2. Tumor factors and pCR outcomes of patients 2.Innovations in pathology, molecular biology and drug development have enabled HER2-positive breast cancer (BC), a historically aggressive subtype, to become one with impressive outcomes. The rates of pCR were 29.3% in the AR-positive group and 43.2% in the AR-negative group (p=0.007). There was a significant difference between the AR-positive group and AR-negative group regarding subtypes (p < 0.001). In the AR-negative group, the HR−/HER2− subtype was most frequent (72.6%), followed by the HR+/HER2− subtype (14.7%). Regarding the subtypes, HR+/HER2−, HR+/HER2+, HR−/HER2+, and HR−/HER2− subtypes comprised 46.9%, 23.6%, 20.4%, and 9.1% of the AR-positive group, respectively. Ki-67 levels were significantly lower in the AR-positive group in comparison to the AR-negative group (38.6☒0.1 vs. The AR-positive group had significantly higher ER positivity and PR positivity, and HER2 positivity than the AR-negative group. Regarding the AR receptor status, the AR-positive group had significantly higher clinical T stages 3, and 4 than the AR-negative group (32.3% vs. The mean age (±standard deviation) at diagnosis was 50.0☙.6 years. Five hundred twenty-nine patients (84.8%) were AR-positive and 95 patients (15.2%) were AR-negative. Table 1 summarized the clinicopathologic characteristics of the patients. Characteristics of the study populationĪ total of 624 breast cancer patients who underwent neoadjuvant chemotherapy were included in the analysis. Characteristics of the study population 1. 4.1.2 (R Core Team, Vienna, Austria), and a p-value < 0.05 was considered statistically significant. All statistical analyzes were performed using R ver. In addition, after correcting for significant factors, to confirm the effect of pretreatment AR on pCR, the distribution of pretreatment AR and pCR in subgroups by subtype was summarized using percentages, and the relationship was confirmed using the chi-square test or Fisher exact test. After including all clinical factors, the backward elimination method with criterion p-value < 0.05 was used to identify significant factors. Clinical factors affecting pCR were identified using a multivariable logistic regression model. For clinical factors according to pretreatment AR and pCR, depending on the types of variables, the chi-square test or Fisher exact test was used for categorical variables, and the t test was used for continuous variables. Patient characteristics were summarized by the mean and standard deviation for continuous variables, and frequency counts with percentages for categorical variables.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |